

Terry E Goldberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3571361/publications.pdf>

Version: 2024-02-01

44
papers

3,168
citations

331670

21
h-index

289244

40
g-index

49
all docs

49
docs citations

49
times ranked

4618
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 240-248.	3.6	3
2	Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. <i>JAMA Psychiatry</i> , 2022, 79, 359.	11.0	26
3	Validity of the Web-Based, Self-Directed, NeuroCognitive Performance Test in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1131-1136.	2.6	5
4	The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1567-1580.	2.6	7
5	A machine learning approach to identifying delirium from electronic health records. <i>JAMIA Open</i> , 2022, 5, .	2.0	2
6	Associations of APOE e2 genotype with cerebrovascular pathology: a postmortem study of 1275 brains. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 7-11.	1.9	9
7	Effects of restriction of activities and social isolation on risk of dementia in the community. <i>International Psychogeriatrics</i> , 2021, 33, 1207-1215.	1.0	13
8	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). <i>Contemporary Clinical Trials</i> , 2021, 106, 106425.	1.8	4
9	High-impact rare genetic variants in severe schizophrenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
10	Intact global cognitive and olfactory ability predicts lack of transition to dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 326-334.	0.8	21
11	Association of Delirium With Long-term Cognitive Decline. <i>JAMA Neurology</i> , 2020, 77, 1373.	9.0	226
12	Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12024.	2.4	1
13	Advancing Computerized Cognitive Training for MCI and Alzheimer's Disease in a Pandemic and Post-pandemic World. <i>Frontiers in Psychiatry</i> , 2020, 11, 557571.	2.6	18
14	Association of APOE e2 genotype with Alzheimer's and non-Alzheimer's neurodegenerative pathologies. <i>Nature Communications</i> , 2020, 11, 4727.	12.8	46
15	Composite cognitive and functional measures for early stage Alzheimer's disease trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12017.	2.4	36
16	Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. <i>PLoS ONE</i> , 2020, 15, e0228064.	2.5	9
17	Comments about SuperAging and SuperAgers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 564-565.	2.4	2
18	Breadth and depth of working memory and executive function compromises in mild cognitive impairment and their relationships to frontal lobe morphometry and functional competence. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 170-179.	2.4	24

#	ARTICLE	IF	CITATIONS
19	Cognitive training and neuroplasticity in mild cognitive impairment (COG-IT): protocol for a two-site, blinded, randomised, controlled treatment trial. <i>BMJ Open</i> , 2019, 9, e028536.	1.9	25
20	DTâ€œ1â€œ06: ASSOCIATION OF APOE E2 GENOTYPE WITH NEUROPROTECTION: A TRANSâ€œDIAGNOSTIC STUDY OF 1557 BRAINS IN THE NACC V 10 DATA BASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1487.	0.8	0
21	The Age-Related Perfusion Pattern Measured With Arterial Spin Labeling MRI in Healthy Subjects. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 214.	3.4	49
22	Differential medial temporal lobe morphometric predictors of itemâ€œand relationalâ€œencoded memories in healthy individuals and in individuals with mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 238-246.	3.7	8
23	Cerebral blood flow measured by arterial spin labeling MRI at resting state in normal aging and Alzheimerâ€™s disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 72, 168-175.	6.1	142
24	Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 30-39.	0.1	6
25	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1085-1097.	2.6	12
26	Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 39, 165-173.	3.1	21
27	Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimerâ€™s Disease: Patterns of Protection and Degeneration. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 969-978.	2.6	10
28	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 103-111.	2.4	191
29	Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2015, 1, 37-45.	3.7	23
30	Reply to: The Impact of Magnetic Resonance Spectroscopy in Elucidating the Role of Apolipoprotein E Epsilon4 in Preclinical Alzheimerâ€™s Disease. <i>Biological Psychiatry</i> , 2015, 77, e41-e42.	1.3	0
31	Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2015, 41, 1237-1247.	4.3	45
32	Extension and refinement of the predictive value of different classes of Âmarkers in ADNI: Fourâ€œyear followâ€œup data. <i>Alzheimer's and Dementia</i> , 2014, 10, 704-712.	0.8	59
33	Antidepressants for cognitive impairment in schizophrenia â€œ A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2014, 159, 385-394.	2.0	48
34	APOE Genotype Modulates Proton Magnetic Resonance Spectroscopy Metabolites in the Aging Brain. <i>Biological Psychiatry</i> , 2014, 75, 686-692.	1.3	31
35	Development and Cross-Validation of the UPSA Short Form for the Performance-Based Functional Assessment of Patients With Mild Cognitive Impairment and Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 915-922.	1.2	50
36	Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative. <i>Archives of General Psychiatry</i> , 2011, 68, 961.	12.3	293

#	ARTICLE	IF	CITATIONS
37	Performance-Based Measures of Everyday Function in Mild Cognitive Impairment. <i>American Journal of Psychiatry</i> , 2010, 167, 845-853.	7.2	129
38	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). <i>Schizophrenia Research</i> , 2008, 102, 108-115.	2.0	281
39	Neurobiology of cognitive aging: Insights from imaging genetics. <i>Biological Psychology</i> , 2008, 79, 9-22.	2.2	65
40	Levels of processing effects on recognition memory in patients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 74, 101-110.	2.0	28
41	Executive Subprocesses in Working Memory. <i>Archives of General Psychiatry</i> , 2003, 60, 889.	12.3	562
42	Verbal working memory dysfunction in schizophrenia: use of a Brown-Peterson paradigm. <i>Psychiatry Research</i> , 1995, 56, 155-161.	3.3	102
43	Further Evidence for Dementia of the Prefrontal Type in Schizophrenia?. <i>Archives of General Psychiatry</i> , 1987, 44, 1008.	12.3	493
44	Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	12